pros and cons of glp 1 agonists glp-1 Advantages and disadvantages lixisenatide therapy In my latest blog, The

Store in a cool dry place

Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88

By Michael S

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

Mattioli Introduction GLP-1 agonists like liraglutide have become a powerful tool for weight management, but they often come with digestive side effects and concerns about long-term use

The FDA has laid out post-marketing safety testing requirements for Lilly's weight-loss pill Foundayo, including clinical trials.